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Innovations
Cortex Pharmaceuticals, Inc.
Maintaining Brain Function Goes a Long Way
the hippocampus that are particu- trials for the treatment of Alzhei-
mer’s and MCI.larly vulnerable to AD. Interestingly,
Cortex’s lead AMPAKINE com-AMPAKINE compounds can differ-
Diseases such as Alzheimer’s and
schizophrenia can result in such a
devastating loss of a person’s pur-
pose and ability to reason that reme- pound, CX516, was successful inentially affect various types of brain
dies for these and other neurological proof-of-principle studies and isfunction. “The pure cognitive func-
and psychiatric disorders remain currently undergoing phase II clini-tion of the agent ultimately triggers
among the most critical health is- cal trials. In preclinical studies,LTP. It turns out that this pathway is
sues for millions of people around CX516 showed distinct memory en-critical…in schizophrenia,” explains
the world. Cortex Pharmaceuticals, hancement in mice and monkeys,Roger Stoll, President and Chief Ex-
Inc. in Irvine, California, engages in and in phase I studies, this com-ecutive Officer of Cortex. Studies
the discovery, development, and pound showed dose-dependenthave shown that glutamatergic ac-
commercialization of novel com- memory enhancement in both youngtivity could underlie some symp-
pounds that enhance memory and and elderly healthy subjects, re-toms of schizophrenia. Stoll points
cognition and thus impact a range sulting in enhanced performance inout that LTP targets are “missing in
of disorders. individuals tested for visual associa-most of the drugs being used in
Since 1993, Cortex has been ar- tion, odor recognition, and visuo-schizophrenia.” There is currently a
duously refining their patented AMPA spatial maze acquisition. In animalwidespread pharmaceutical search
(-amino-3-hydroxy-5-methyl-4- models, CX516 displayed syner-for drugs that affect the cognitive
isoxazolepropionic acid) receptor gistic effects with antipsychotic drugsportion of schizophrenia.
modulator compounds termed AM- used to treat schizophrenia. Such
PAKINES. The AMPA glutamate re- synergy shows promise and could
ceptors are one of three types of potentially allow for a decrease in
There is currently a wide-ionotropic glutamate receptors re- the antipsychotic dosage, alleviat-
ing some of the extra-pyramidal sidesponsible for binding the excitatory spread pharmaceutical
neurotransmitter L-glutamate. Acti- effects of these drugs, e.g., involun-search for drugs that af-vation of AMPA-type receptors pro- tary body movements. CX516 is cur-
fect the cognitive portionpagates the depolarization required rently in phase II trials in medicated
(clozapine or olanzapine) schizophre-to unblock the voltage-sensitive of schizophrenia.
NMDA (N-methyl-D-aspartate) glu- nia subjects.
tamate receptors, which then admit CX516 is also being studied as
calcium into the dendritic side of the a potential therapeutic for Fragile XHaving one family of compounds
synapse and induce the long-term syndrome and autism and is the sub-affect multiple functions of the brain
potentiation (LTP) shown to have ject of a government-funded studycan be advantageous but has also
predictable effects on memory. Es- for narcolepsy and other sleep dis-contributed to Cortex’s struggle to
tablished correspondence between orders. From preliminary results it isovercome skepticism about whether
the LTP and memory enhancement hoped that AMPAKINE compoundsenhancing the excitatory processes
prompted the search for AMPA re- could increase attention, executive
in the brain could be done safely.
ceptor activators. AMPAKINE com- function, memory, and language in
Such skepticism has led to difficul-pounds bind to one or more modula- order to improve the quality of life for
ties with funding, and, although re-tory sites distinct from either the persons with Fragile X retardation,
search has been going well, the pro-agonist/antagonist site or the alloste- autism, as well as Attention Deficit
cess of clinical trials is too costly andric benzothiadiazide site of the AMPA Hyperactivity Disorder (ADHD). The
time consuming for this company toreceptor complex. AMPAKINE tech- narcolepsy studies are funded by
pursue. To alleviate some of the bur-nology was invented and developed the Defense Advanced Research
dening costs, Cortex has licensedby Dr. Gary Lynch at the University of Projects Agency (DARPA) in hopes
two of its leading AMPAKINE com-California, Irvine. Lynch’s work and of maintaining critical thinking in
pounds to larger pharmaceutical de-expertise has since been adopted persons with sleep deprivation.
velopers. Organon obtained the li-by Cortex, and a successful collabo- Though CX516 has shown prom-
cense for Org-24448 in 1999 and isration has been maintained. ise in several studies, successors
currently carrying out phase II trialsA compound that enhances mem- with improved functionality are likely
for efficacy in schizophrenia withory is an obvious therapy for Alzhei- to be the compounds of choice for
this compound. Cortex establishedmer’s disease (AD) and mild cogni- specific diseases. From continued
an alliance with Servier Pharmaceu-tive impairment (MCI). In fact, it is research over the last ten years, re-
ticals in 2000 for the development ofknown that the number of glutamate searchers at Cortex and in Dr.
Lynch’s lab at UC Irvine have iso-receptors is decreased in areas of S18986, which is in phase II clinical
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lated more potent AMPAKINE com- duction of BDNF. The ability to in-
duce BDNF in various areas of thepounds for specific activation of
LTP. While most of the AMPAKINE brain has potential in therapies for
Alzheimer’s and Parkinson’s dis-molecules can bind to several AMPA
receptor domains, they have identi- ease as well as spinal cord injuries,
in which increased amounts of BDNFfied specific AMPAKINEs which have
up to a 10-fold greater affinity for could restore neuronal function.
The list of possibilities for AM-specific receptor sites, e.g., GluR1,
GluR4, flip, or flop. Cortex currently PAKINE drugs seems to grow as the
research continues. Cortex is alsohas a family of more than 800 unique
AMPAKINE molecules which are investigating the use of CX516 as an
intravenous drug for coronary by-chemically diverse and appear to
vary in selectivity across a variety of pass patients. Post-surgery, it is not
uncommon for these bypass pa-established disease-based animal
behavior models for neurological tients to experience symptoms of
mild cognitive impairment. In orderand psychiatric disorders. Despite
its proven effectiveness, CX516 has to prevent this memory loss, Cortex
is in the process of producing ana short, one hour half-life and low
potency, requiring multiple doses in intravenous CX516 drug.
All of these possibilities and ave-one day. CX717, however, has a
longer half-life, is 50 times more po- nues of AMPAKINE research have to
be strategically pursued in order fortent, and will likely be one of the re-
placements for CX516 once the nec- Cortex to survive. Roger Stoll has
been with Cortex for just over a yearessary trials have been completed.
A more recent Cortex discovery and has directed the company’s fo-
cus toward the development of AM-is the effect of certain AMPAKINE
compounds on the induction of PAKINEs for Fragile X syndrome, as
this rare disease qualifies for Orphanbrain-derived neurotrophic factor
(BDNF). It was previously demon- Drug application. The Orphan Drug
tract allows a company to bring astrated that activation of excitatory
receptors increased BDNF produc- potentially low-profit drug for a rare
disease to market with shorter de-tion in the adult brain. BDNF is
widely expressed in the adult mam- velopment timelines. In this way, a
profit can be rendered in a shortermalian brain and has been found to
promote survival of all major neu- amount of time. Any profits for Cor-
tex would fund the more lengthy andronal types affected in Alzheimer’s
and Parkinson’s disease. Cortex re- expensive trials for the “block-
buster” drugs like those for Alzhei-searchers surmised that the activa-
tion of AMPA receptors by AMPA- mer’s, Parkinson’s, and schizophre-
nia. “My charge here is to find aKINE drugs could upregulate BDNF
expression. Preclinical studies with pathway on which we can succeed
as a business,” states Stoll. CortexCX614 demonstrated an increase in
BDNF mRNA and protein content in believes that this combined ap-
proach to developing its technologyadult rat brains. Dr. Stoll reports,
“some of our compounds are much may not only create value for its
company but also may bring thera-more efficient at upregulating BDNF
than others.” A series of com- peutic relief to those suffering from
diseases that are currently amongpounds, CX546, CX691, CX614, and
CX691, increased BDNF expression the most difficult to treat.
in different parts of the rat brain. The
Chemistry & Biology invites yourresearch has shown there is more
comments on this topic. Pleaseselectivity with certain structures of
write to the editors at chembiol@AMPAKINEs, and Stoll claims cur-
cell.com.rent research is focused on “trying
to find that mechanism and what Nicole Ballew is a freelance science writer
triggers it.” Finding the specific re- based in Lebanon, NH (nballew@hotmail.
ceptor domain that gives the great- com).
est BDNF expression could lead to
a more complete understanding of
how the AMPAKINE molecules func-
tion. Further studies are expected
to produce a highly specific, highly
potent AMPAKINE molecule for in-
